Scarica l'app Stockscreener
24.95
0.76%
-0.19
Dopo l'orario di chiusura:
24.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DYN Giù?
Forum
Previsione
Precedente Chiudi:
$25.14
Aprire:
$25.26
Volume 24 ore:
1.45M
Relative Volume:
0.68
Capitalizzazione di mercato:
$4.66B
Reddito:
-
Utile/perdita netta:
$-451.71M
Rapporto P/E:
-7.7338
EPS:
-3.2261
Flusso di cassa netto:
$-462.19M
1 W Prestazione:
-4.37%
1M Prestazione:
-1.15%
6M Prestazione:
+70.89%
1 anno Prestazione:
+85.09%
Intervallo 1D:
$24.60
$25.39
Intervallo di 1 settimana:
$24.58
$26.18
Portata 52W:
$11.92
$27.30
Dyne Therapeutics Inc Stock (DYN) Company Profile
Nome
Dyne Therapeutics Inc
Settore
Industria
Telefono
(781) 786-8230
Indirizzo
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
24.95 | 4.85B | 0 | -451.71M | -462.19M | -3.2261 |
VRTX
Vertex Pharmaceuticals Inc
|
557.96 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
843.47 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,053.46 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
148.87 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.87 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-10 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-25 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Iniziato | Bernstein | Mkt Perform |
| 2025-06-11 | Ripresa | Raymond James | Outperform |
| 2025-06-02 | Ripresa | Oppenheimer | Outperform |
| 2025-05-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-13 | Iniziato | Robert W. Baird | Outperform |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-10-24 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Reiterato | Chardan Capital Markets | Buy |
| 2024-04-30 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-20 | Iniziato | H.C. Wainwright | Buy |
| 2023-02-27 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Iniziato | Oppenheimer | Outperform |
| 2023-01-26 | Iniziato | Guggenheim | Buy |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Outperform |
| 2020-10-12 | Iniziato | JP Morgan | Overweight |
| 2020-10-12 | Iniziato | Jefferies | Buy |
| 2020-10-12 | Iniziato | Piper Sandler | Overweight |
| 2020-10-12 | Iniziato | Stifel | Buy |
Mostra tutto
Dyne Therapeutics Inc Borsa (DYN) Ultime notizie
Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - TradingView
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
DYN Stock Gains As It Gears Up For Accelerated Approval Of DMD Therapy: Wall Street Sees 140% Upside - Stocktwits
Q3 EPS Forecast for Dyne Therapeutics Decreased by Analyst - MarketBeat
Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Aegis Wealth Management LLC Invests $3.33 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Insider Selling: Dyne Therapeutics (NASDAQ:DYN) Director Sells $54,012,900.00 in Stock - MarketBeat
Dyne Therapeutics CCO Executes Automatic Sale of 226 Shares to Cover RSU Tax Withholding - Kalkine Media
Dyne Therapeutics CEO John Cox Sells 4,986 Shares to Cover Tax Withholding on RSUs - Kalkine Media
Dyne therapeutics director Jason Rhodes sells $65.2m of common stock - Investing.com
Dyne Therapeutics (DYN) director's preset stock sale via Atlas funds - Stock Titan
Dyne therapeutics CFO Erick Lucera sells $47,225 in stock - Investing.com
Dyne Therapeutics (DYN) CFO sells shares in tax withholding trade - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CCO sells shares to cover taxes - Stock Titan
Dyne Therapeutics (NASDAQ: DYN) CMO has shares sold for tax withholding - Stock Titan
Dyne Therapeutics (DYN) CEO's tax-driven sale to cover RSU taxes - Stock Titan
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook By Investing.com - Investing.com Canada
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Bank of America Corp DE Has $26.17 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
Dyne Therapeutics, Inc. SEC Filing (Aug 13, 2026) - Stock Titan
DYN Company (Nasdaq: DYN) holder plans 4,986-share sale worth $131,034 - Stock Titan
DYN (DYN) insider notice details planned share sale and prior trades - Stock Titan
DYN (DYN) shareholder Doug Kerr plans sale of 2,443 common shares - Stock Titan
Dyne Therapeutics (DYN): Atlas Venture funds report 3.6% beneficial stake in 13G/A - Stock Titan
Dyne Therapeutics (DYN) gains 7.3% institutional holder Janus Henderson - Stock Titan
Dyne Therapeutics stock hits 52-week high at 27.19 USD By Investing.com - Investing.com Nigeria
Dyne Therapeutics stock hits 52-week high at 27.19 USD - Investing.com
Biotech Stocks At 52-Week HighsALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - rttnews.com
The Bull Case For Dyne Therapeutics (DYN) Could Change Following FDA Clearance Of DYNE-302 Trial - webull.com
FMR LLC Expands Dyne Therapeutics Stake: A Strategic Bet on Neur - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week HighHere's What Happened - MarketBeat
Discipline and Rules-Based Execution in DYN Response - Stock Traders Daily
Dyne Therapeutics (DYN) Gets FDA Clearance With Valuation Questions Back In Focus - Sahm
Dimensional Fund Advisors LP Has $17.24 Million Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Inc (DYN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dyne Therapeutics, Inc. Revenue Breakdown – NASDAQ:DYN - TradingView
FMR LLC (DYN) discloses 6.8% Dyne Therapeutics stake in amended ownership filing - stocktitan.net
Dyne Therapeutics stock hits 52-week high at 26.8 USD By Investing.com - Investing.com UK
Dyne Therapeutics stock hits 52-week high at 26.8 USD - Investing.com
Dyne Therapeutics (NASDAQ:DYN) Reaches New 52-Week HighShould You Buy? - MarketBeat
Analysts Offer Insights on Healthcare Companies: Dyne Therapeutics (DYN) and Crescent Biopharma (CBIO) - The Globe and Mail
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 56% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Bank of New York Mellon Corp Buys 48,119 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Weekly Recap: BLA accepted for Z‑Rostudirsen and RBC raises PT to $35 - tradingview.com
Dyne Therapeutics, Inc. $DYN Shares Purchased by Renaissance Technologies LLC - MarketBeat
Dyne Therapeutics, Inc. $DYN Shares Purchased by Perceptive Advisors LLC - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) Cut to Strong Sell at Wall Street Zen - MarketBeat
Dyne Therapeutics Inc Azioni (DYN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dyne Therapeutics Inc Azioni (DYN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Rhodes Jason P | Director |
Aug 13 '26 |
Sale |
26.20 |
426,412 |
11,171,994 |
751,411 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Aug 13 '26 |
Sale |
26.28 |
226 |
5,939 |
153,982 |
| Kerr Douglas | Chief Medical Officer |
Aug 13 '26 |
Sale |
26.28 |
1,556 |
40,892 |
167,599 |
| Cox John | CEO & President |
Aug 13 '26 |
Sale |
26.28 |
4,986 |
131,032 |
363,165 |
| Lucera Erick | Chief Financial Officer |
Aug 13 '26 |
Sale |
26.28 |
1,797 |
47,225 |
119,766 |
0.64%
0.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):